Human Mesenchymal Stromal Cells (hMSCs) are cultured in vitro with different media. Limits on their use in clinical settings, however, mainly depend on potential biohazard and inflammation risks exerted by xenogeneic nutrients for their culture. Human derivatives or recombinant materials are the first choice candidates to reduce these reactions. Therefore, culture supplements and materials of autologous origin represent the best nutrients and the safest products.
Introduction
Human Mesenchymal Stromal Cells (hMSCs) represent one of the best cell sources for use in tissue engineering for promoting osteogenesis 1, 2 . They are easily isolated from bone marrow and other adult tissues, and express typical surface markers such as CD90, CD105, CD73 1 . Moreover, they can differentiate into several cell types, such as osteoblasts, chondrocytes and adipocytes 3 . Their therapeutic effects are attributed to their regenerative and trophic properties 4 . hMSCs could be used in orthopedic surgery, as well as in other regenerative clinical applications. They are preferably combined with scaffolds, to improve the clinical outcome 5 .
Compared to other materials, the fibrin gel shows interesting properties such as adhesiveness, resorption and efficient transport of nutrients, which make it extremely useful for a variety of tissue engineering applications 6, 7 .
The main challenge in translating a tissue engineering approach into clinical applications is obtaining a fully-biocompatible and biosafe scaffold and a xeno-free culture medium that avoids any infective or reactive effect.
In our method, fibrin gel, derived from the patient's own blood, and autologous serum, for in vitro hMSCs culture, were employed as a possible therapeutic solution in the orthopedic field 8 .
For clinical purposes, hMSCs are usually administrated via two main procedures: (i) the "one-step" procedure (i.e., minimal manipulation), which allows the auto transplant of bone marrow, either whole or concentrated (i.e., mononuclear cells), during surgery; and (ii) the "two-step" procedure (i.e., extensive manipulation), which is based on the ex vivo expansion of hMSCs to increase their yield before implantation, and requires GMP facilities . Thus, hMPCs may play a significant role in the regenerative process when compared with hMSCs alone 12, 13 . Finally, short-term osteo-induction pushes hMSCs to start their differentiation into the osteogenic lineage without losing their proliferative potential and viability 12 . These results confirm previous studies that have reported enhanced in vivo bone formation by hMSCs, followed by a preculture in osteogenic medium 14 . Moreover, an autologous plasma clot as a scaffold for cell delivery can be easily manipulated by the surgeon and molded to fit the shape of the bone cavity 13 . Therefore, this method can be extremely useful for those researchers and clinicians who aim at translating their hMSC-based therapy from the bench to the bedside in orthopedic applications.
Protocol
The present protocol was developed in accordance with the World Medical Association's Declaration of Helsinki regarding the ethical conduct of research involving humans. It was approved by the Ethical Committee of the Azienda Ospedaliero-Universitaria Pisana.
NOTE:
Bone marrow was obtained from patients undergoing routine total hip replacement surgery (according to step 1.1) 15 ; plasma for the clot preparation was obtained from autologous peripheral blood 13 ; autologous serum, as a supplement for the culture medium, was collected from an autologous whole-blood apheresis. All the patients received detailed information about the procedure and signed a written consent form.
Collection of the Bone Marrow Sample
1. Collect bone marrow from the femoral medullary canal after a total hip replacement surgery (for research studies). Briefly, during the surgical preparation of the medullary canal to house the prosthetic stem, collect the marrow blood that overflows (about 10 -15 mL, depending on the prosthesis size) 15 . OR 2. Collect bone marrow aspirate from the iliac crest under local anesthesia, following standard hematologic procedure about 20 -30 d in advance (for clinical applications) 16 . NOTE: In both cases heparinized syringes (to prevent clot formation) must be used for bone marrow recovery. 
Preparation of Autologous Plasma

Preparation of the Autologous Serum
1. Transfer the unit of plasma into a transfer bag using a spike. Disconnect the filled bag by welding and weigh the bag to calculate the volume of plasma ( Figure 1A ). 2. Coagulate the autologous plasma by injecting calcium gluconate 100 mg/mL at 10% w/v through the port connector ( Figure 1B) . After mixing the bag, place it at 4 °C O/N without shaking to facilitate clot formation. 3. Centrifuge the bag at 4,900 × g for 15 min at RT. Take the centrifuge bucket out of the centrifuge and remove the bag carefully (follow the manufacturer's guidelines for the preparation of platelet lysate) ( Figure 1C ). 4. Isolate the clot just above the clamp to facilitate filtration. Connect the filtration kit to the transfer bag using a spike placed into the outlet port of the filtration kit. 5. Hang the bag and open the blue clamp to let the serum flow by gravity. Do not apply pressure to the filter to avoid transfer of fibrin into the bag. After filtration, seal the tubing and remove the bag (follow the manufacturer's guidelines for preparation of platelet lysate). 6. Connect a dedicated line to the final bag and transfer serum into 50 mL tubes under a laminar flow bench to avoid microbial contamination. 7. Take a sample with a syringe to test the absence of fibrinogen and perform a sterility test for aerobic and anaerobic bacterial cultures 17 . Label the tubes appropriately and freeze them at -20 °C until usage.
Preparation of the Expansion Medium
1. Prepare 500 mL of complete proliferation medium. To Dulbecco's Modified Eagle Medium -Low Glucose (DMEM-LG), add 10% autologous serum (obtained as described in section 3), 2 mM glutamine, 1% antibiotic solution and 1% antimycotic solution. Sterile-filter the complete proliferation medium.
Isolation of hMSCs from the Bone Marrow
1. Transfer the bone marrow sample (5 -10 mL) from the syringe into a 50 mL conical tube and dilute it with sterile saline (ratio 1:4). Vortex the 50 mL tube for 30 s to disaggregate the cell clusters. 2. Warm the density gradient (density 1.077 g/L; see Table of Materials) to RT before usage and layer the diluted bone marrow gently (to prevent mixing both layers) onto the density gradient by adding 20 mL of the sample to 15 mL of density gradient for each 50 mL tube (Figure 2A ). 3. Centrifuge at 400 × g without brake at 25 °C for 30 min, then collect the mononuclear fraction at the liquid-liquid interface and transfer it to a new 50 mL tube using a sterile 5 mL pipette.
4. Wash the collected mononuclear fraction twice with complete proliferation medium and centrifuge the tubes at 400 × g for 10 min at 25 °C to obtain cell pellets. 5. Discard the supernatant and gently resuspend each cell pellet in 5 mL of complete proliferation medium. Dilute at a 1:100 ratio for cell counting. 6. Count the cells using a hemocytometer after a 1:1 dilution with Trypan Blue staining to evaluate cell viability. Add fresh medium to the flasks and replace half of it twice a week, until 70 -80% confluency (primary culture, Passage 0 (P0)) ( Figure 2B ). 5. Recover the cells by using a specific recombinant animal free protease (see Table of Materials; use 3 mL of the solution per flask as recommended by the manufacturer) and incubate at 37 °C and 5% CO 2 for 10 min. Add 6 mL of complete proliferation medium per flask and collect in one 50 mL tube. Repeat step 5.6. NOTE: IMPORTANT: The use of this protease instead of trypsin allows the recovery of some Mesodermal Progenitors Cells (MPCs) present in the culture, which is trypsin resistant. 6. For further expansion, replate the cell suspension at 2,000 -3,000 cells/cm 2 in new 75 cm 2 TC flasks (P1) (Figure 2C ). Figure 2D) . NOTE: Different staining methods can be used to assess multilineage differentiation. LG to obtain a 100 µg/mL solution (Solution 2B, working solution). Stock aliquots of solutions 2A and 2B at -20 °C until usage. 3. Upon usage prepare fresh osteogenic medium as follows: add DMEM-LG with 10% autologous serum, 50 µg/mL ascorbic acid and 0.4 µg/mL hydrocortisone. Sterile-filter the osteogenic medium.
Culture of hMSCs in the Presence of Autologous Serum
Use aliquots of cells to evaluate the differentiation potentials of MSCs towards osteogenic, adipogenic and chondrogenic lineages. Perform differentiation assays following the manufacturer's recommendations (
Preparation of an Osteogenic Medium with Pharmaceutical Supplements
Osteogenic Pre-induction and Recovery of hMSCs
1. Completely remove the proliferation medium and add osteogenic medium 96 h before cell harvesting (i.e., 80 -90% confluence is usually reached in 7 d). Provide an additional osteogenic medium change 24 h before cell harvesting. 2. Detach the cells as described in step 6.5 and gently resuspend the pellet adding 2 mL of complete proliferation medium in a 50 mL tube.
NOTE: Cell viability may be reduced (about 10%) as a result of osteoinduction. Cellular aggregates can be observed. 3. After counting, wash the cells with complete proliferation medium and centrifuge at 300 × g for 5 min. Resuspend the pellet gently at 1 -2 x 10 6 viable cells/2 mL of autologous plasma (see section 2) per 50 mL tube.
Preparation of hMSC/fibrin Clot Constructs
1. Add 150 µl of calcium gluconate at 100 mg/mL to each 50 mL tube obtained from step 8.3. and resuspend the cells under gentle shaking. 2. Incubate the cells at 37 °C and 5% CO 2 for 15 -30 min to obtain hMSC/fibrin clot constructs ( Figure 3A) . Prepare a fibrin clot construct without cells to be used as a control. NOTE: IMPORTANT: It is recommendable to prepare this control clot at least 2 h before the cell viability assay, as it takes 30 min or more to crosslink.
Cell Viability Assay
1. Remove the liquid from the 50 mL tubes and add 1 mL of complete proliferation medium containing 10% v/v cell viability reagent (AB; see Table of Materials), according to the manufacturer's guidelines. 2. Incubate the tubes at 37 °C and 5% CO 2 for 3 h. Measure the absorbance at 570 nm with a reference wavelength of 600 nm (AB at time 0; t0). 3. Discard the supernatant and add 2 mL of fresh complete proliferation medium. Incubate at 37 °C, 5% CO 2 O/N. The next day (AB at time 24 h; t24), repeat steps 10.1 to 10.3 ( Figure 3B ). 
Discussion
The critical steps of this protocol concern the use of human adult serum and protease, which allow to obtain a biosafe hMSC therapy. In particular, the human adult serum enables isolation and maintenance, while protease ensures the harvest, of MPCs. These are immature cells present in the bone marrow that can give rise to fresh hMSCs, thus ensuring a reservoir of viable hMSCs along the culture time. Not all the MPCs can be collected, since increasing the exposure time to the protease activity is detrimental to hMSC viability. For this reason, a 10 min protease incubation was selected as optimal compromise between the recovery of MPCs and the viability of hMSCs. Another critical step is osteodifferentiation time. Indeed, an extensive in vitro osteodifferentiation would considerably reduce cell viability, thus affecting the final bone formation in vivo. The last critical step consists in availing of an autologous bioresorbable scaffold, which is obtained by embedding the cells (hMSCs and MPCs) in a fibrin gel from plasma clotting.
A key step to enhance the yield of MPCs is to seed mononuclear cells at higher concentration. Using apheresis procedures to obtain plasma and treating it with calcium gluconate makes it possible to achieve autologous serum in large amounts. It has been observed that human serum as a medium supplement is comparable to Fetal Bovine Serum (FBS) in hMSC cultures. However, in our experience, a complete medium supplemented with FBS contributes to faster senescence than human adult serum. A significant step is that of administering a minimal osteoinduction to hMSCs. Indeed, this treatment leads the cells to easily differentiate towards the osteogenic lineage, thus being useful to avoid further cell transformation in vivo. To maintain a good viability of minimally osteoinduced hMSCs, it is recommended to follow carefully the recommendations described in steps 6.5. and 8.2., including handling, centrifuging and medium amounts to be added. If an apheresis procedure is not available, it is still possible to carry out this protocol by performing multiple blood draws to the patient or, in alternative, by purchasing pooled AB sera. Obviously, in order to bring this protocol from the bench-to-bedside, it is mandatory to have GMP cell factories, or equivalents, available.
Limitations to the application of this technique concern the anemic, hematological-oncology and orthopedic patients affected by osteomyelitis., Drawing large amounts of blood from anemic patients, should be avoided. In oncologic patients, the quality of the cell samples is affected by chemotherapy treatments, whereas in osteomyelitis patients the infection can affect the final outcome. In all the cases in which the autologous serum is insufficient or unsuitable, pooled male AB sera represent a good alternative.
Using cell/fibrin clot constructs for possible clinical applications is crucial to release a completely autologous cell therapy, which could be easy to handle and mold during surgery, resulting in excellent outcomes to treat bone non-unions 13 . For clinical purposes, hMSCs are usually administered via two main procedures: minimal manipulation and extensive manipulation 9 . To overcome the problems related to an extensive ex vivo culture, such as abnormalities in cell morphology and size 18 , we performed a short time ex vivo cell expansion and osteo-differentiation (only 4 d).
The xeno-free protocol described in this paper, together with the short cell expansion and osteodifferentiation times, demonstrated to be relevant in clinics in order to obtain fast bone production in vivo, without evidence of tissue overgrowth and transformation, thus confirming its efficacy and long-term safety in bone repair (Figure 5 ) 13 .
The methodology presented in this report is aimed at demonstrating the efficacy and safety of hMSC in vitro expansion in autologous conditions for possible use in orthopedic surgery. This protocol employs hMSCs isolated from bone marrow and cultured in a medium supplemented with autologous serum and embedded in autologous fibrin clot, thus ensuring a completely autologous cell therapy. The two-fold osteogenic induction, just before the second detachment, improves hMSC ability to differentiate into osteoblasts. As a result, this technique is particularly suitable for applications in bone defects, since it is not limited to pseudarthrosis. Possible future applications could involve talus cyst and bone loss management.
